193 related articles for article (PubMed ID: 30350218)
21. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence.
Zhong Y; Lin PJ; Cohen JT; Winn AN; Neumann PJ
Value Health; 2015 Mar; 18(2):308-14. PubMed ID: 25773567
[TBL] [Abstract][Full Text] [Related]
22. Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.
Kim DD; Silver MC; Kunst N; Cohen JT; Ollendorf DA; Neumann PJ
Pharmacoeconomics; 2020 Oct; 38(10):1135-1145. PubMed ID: 32696192
[TBL] [Abstract][Full Text] [Related]
23. Family Spillover Effects: Are Economic Evaluations Misrepresenting the Value of Healthcare Interventions to Society?
Leech AA; Lin PJ; D'Cruz B; Parsons SK; Lavelle TA
Appl Health Econ Health Policy; 2023 Jan; 21(1):5-10. PubMed ID: 35997896
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of preventive case management for parents with a mental illness: a randomized controlled trial from three economic perspectives.
Wansink HJ; Drost RMWA; Paulus ATG; Ruwaard D; Hosman CMH; Janssens JMAM; Evers SMAA
BMC Health Serv Res; 2016 Jul; 16():228. PubMed ID: 27388373
[TBL] [Abstract][Full Text] [Related]
25. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
26. Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review.
Padula WV; Chen HH; Phelps CE
Appl Health Econ Health Policy; 2021 Mar; 19(2):155-162. PubMed ID: 32812212
[TBL] [Abstract][Full Text] [Related]
27. A systematic review of cost-effectiveness analyses alongside randomised controlled trials of acupuncture.
Kim SY; Lee H; Chae Y; Park HJ; Lee H
Acupunct Med; 2012 Dec; 30(4):273-85. PubMed ID: 23099289
[TBL] [Abstract][Full Text] [Related]
28. Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease.
Zhou T; Chen Z; Li H; Xie F
Med Decis Making; 2021 Aug; 41(6):685-692. PubMed ID: 33813938
[TBL] [Abstract][Full Text] [Related]
29. Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.
Tew M; Clarke P; Thursky K; Dalziel K
Pharmacoeconomics; 2019 Jul; 37(7):931-941. PubMed ID: 30864067
[TBL] [Abstract][Full Text] [Related]
30. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses.
Picavet E; Cassiman D; Simoens S
J Clin Pharm Ther; 2015 Jun; 40(3):304-7. PubMed ID: 25891411
[TBL] [Abstract][Full Text] [Related]
31. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
33. Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review.
Neovius M; Narbro K
Int J Obes (Lond); 2008 Dec; 32(12):1752-63. PubMed ID: 18982009
[TBL] [Abstract][Full Text] [Related]
34. Is the societal approach wide enough to include relatives? Incorporating relatives' costs and effects in a cost-effectiveness analysis.
Davidson T; Levin LA
Appl Health Econ Health Policy; 2010; 8(1):25-35. PubMed ID: 20038191
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis in minimally invasive spine surgery.
Al-Khouja LT; Baron EM; Johnson JP; Kim TT; Drazin D
Neurosurg Focus; 2014 Jun; 36(6):E4. PubMed ID: 24881636
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
Tunis SL
Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies.
Chapman RH; Stone PW; Sandberg EA; Bell C; Neumann PJ
Med Decis Making; 2000; 20(4):451-67. PubMed ID: 11059478
[TBL] [Abstract][Full Text] [Related]
38. The changing face of the cost-utility literature, 1990-2012.
Neumann PJ; Thorat T; Shi J; Saret CJ; Cohen JT
Value Health; 2015 Mar; 18(2):271-7. PubMed ID: 25773562
[TBL] [Abstract][Full Text] [Related]
39. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis.
Holubar M; Stavroulakis MC; Maldonado Y; Ioannidis JP; Contopoulos-Ioannidis D
PLoS One; 2017; 12(3):e0172414. PubMed ID: 28249046
[TBL] [Abstract][Full Text] [Related]
40. Variations in cost calculations in spine surgery cost-effectiveness research.
Alvin MD; Miller JA; Lubelski D; Rosenbaum BP; Abdullah KG; Whitmore RG; Benzel EC; Mroz TE
Neurosurg Focus; 2014 Jun; 36(6):E1. PubMed ID: 24881633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
